BACKGROUND: Percutaneous @entity432 ( @entity432 ) is a nonpharmacologic approach for @entity64 prevention in @entity955 ( @entity955 ). No direct comparisons to novel oral anticoagulants (OACs) exists, limiting decision making on the optimal strategy for @entity64 prevention in @entity955 @entity1 . Addressing this gap in knowledge is timely given the recent debate by the US Food and Drug Administration regarding the effectiveness of @entity432 . OBJECTIVE: To assess the cost-effectiveness of @entity432 and novel OACs relative to @entity1229 in @entity1 with new-onset @entity955 without contraindications to OAC. DESIGN: A cost-utility analysis using a @entity1 -level Markov micro-simulation decision analytic model was undertaken to determine the lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) of @entity432 and all novel OACs relative to @entity1229 . Effectiveness and utility data were obtained from the published literature and cost from the Ontario Drug Benefits Formulary and Case Costing Initiative. RESULTS: @entity1229 had the lowest discounted QALY (5.13 QALYs), followed by @entity3926 (5.18 QALYs), @entity3925 and @entity432 (5.21 QALYs), and @entity5424 (5.25 QALYs). The average discounted lifetime costs were  15 776 for @entity1229 ,  18 280 for @entity3925 ,  19 156 for @entity5424 ,  20 794 for @entity3926 , and  21 789 for @entity432 . @entity5424 dominated @entity3926 and @entity432 and demonstrated extended dominance over @entity3925 . The ICER for @entity5424 relative to @entity1229 was  28 167/QALY. @entity5424 was preferred in 40.2% of simulations at a willingness-to-pay threshold of  50 000/QALY. LIMITATIONS: Assumptions regarding clinical and methodological differences between published studies of each therapy were minimized. CONCLUSIONS: @entity5424 is the most cost-effective therapy for @entity64 prevention in @entity1 with new-onset @entity955 without contraindications to OAC. Uncertainty around this conclusion exists, highlighting the need for further research.

A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for XXXX Prevention in @entity1 with New-Onset @entity955 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['Apixaban', 'apixaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['nonvalvular atrial fibrillation', 'NVAF'] @entity432 :: ('MESH:D001157', 'Disease') :: ['LAAO', 'left atrial appendage occlusion'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['Warfarin', 'warfarin']
@entity64 :: (MESH:D020521,Disease) :: ['Stroke']
